The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multiple sclerosis (MS) centers. Data collection was carried out from April 16, 2024 to September 26, 2024.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Demographics: Number of Patients by Age
Timeframe: Baseline
Demographics: Number of Patients by Gender
Timeframe: Baseline
Time Between MS Diagnosis and Treatment Initiation
Timeframe: Baseline
Time Between SPMS Diagnosis and Treatment Initiation
Timeframe: Baseline
Time Between First Symptoms and Treatment Initiation
Timeframe: Baseline
Number of Patients by Clinical Characteristic Category
Timeframe: Baseline
Number of Patients Categorized by Type of Treatment Received Before Initiation of Siponimod
Timeframe: Baseline
Number of Patients by DMT Received Before Initiation of Siponimod
Timeframe: Baseline
Duration of the Washout Period After Other DMTs and Before Initiation of Siponimod
Timeframe: Baseline
Number of Patients by Reason for Switching From Other DMTs to Siponimod
Timeframe: Baseline
Duration of Siponimod Therapy
Timeframe: Up to 2 years